Research programme: phosphodiesterase type 4 inhibitors - Stiefel

Drug Profile

Research programme: phosphodiesterase type 4 inhibitors - Stiefel

Alternative Names: Atopik; Catramilast; R115500

Latest Information Update: 24 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Barrier Therapeutics Inc
  • Developer Stiefel Laboratories
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Atopic dermatitis

Most Recent Events

  • 30 Mar 2007 Preclinical development is ongoing
  • 17 Jun 2004 Preclinical trials in Atopic dermatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top